The Effectiveness of Triple Fixed-Dose Combination Therapy in the Management of Uncontrolled Arterial Hypertension

ORIGINAL ARTICLE
Shukhrat M. Masharipov, Khurshid Kh. Ataniyazov, Dilafruz Yu. Shukurova, Gulnoz A. Khamidullaeva, Guzal J. Abdullaeva, Ravshanbek D. Kurbanov

 
International Journal of Biomedicine. 2020;10(4):334-341.
DOI: 10.21103/Article10(4)_OA1
Originally published December 10, 2020

Abstract: 

The aim of our study was to identify patients with uncontrolled hypertension (UCH) who were resistant to previous antihypertensive therapy (AHT) and to assess the clinical efficacy of the fixed-dose triple combination (FDTC) therapy during 6 months.
Methods and Results: The study included 156 patients with UCH. The mean age of patients was 57.81±10.8 years; the average duration of AH was 8.87±5.34 years. According to the questionnaire data, all patients received dual or triple free-combination AHT, but did not reach the target blood pressure (BP) level. After the screening stage, all patients were discontinued from previous therapy and assigned to the FDTC therapy. Patients initially taking angiotensin-converting enzyme inhibitors (n=96/61.5%) were switched to single-pill triple combination (SPTC) of perindopril, indapamide and amlodipine (Per/Ind/Aml [5mg/1.25mg/5mg]). Patients initially taking angiotensin receptor blockers (n=60/38.5%) were switched to SPTC of telmisartan, hydrochlorothiazide and amlodipine (Tel/HCTZ/Aml [40mg/12.5mg/5mg]). The primary target level for SBP and DBP was <140mmHg and <90mmHg, respectively. With good tolerability of therapy, we aimed for the recommended target level of SBP/DBP (<130mmHg/<80 mmHg).
All patients underwent the following examinations: assessment of traditional risk factors, physical examination, clinical and biochemical laboratory methods, 12-lead ECG, echocardiography, pulse contour analysis, and 24-hour ambulatory blood pressure monitoring.
The results of our study showed that the FDTC therapy at the indicated initial doses in patients with UCT made it possible to achieve the primary target BP level in 73.7% of patients after 3 months of treatment. A further increase in SPTC doses made it possible to increase the number of patients (after 6 months of treatment)who achieved the primary goal to 92.3%, and the recommended goal in 82.4% of patients.
After 6 months of treatment, against the background of selected doses of SPTC, 7.7% of patients were diagnosed with treatment-resistant hypertension.
Conclusion: Markers of UCH are high SBP, DBP, and increased pulse wave velocity, which requires the maximum doses of a full-dose SPTC of antihypertensive drugs (Per/Ind/Aml or Tel/HCTZ/Aml), without wasting time on titration of drug doses.

Keywords: 
uncontrolled hypertension • antihypertensive drug • fixed-dose triple combination • treatment-resistant hypertension
References: 
  1. Riley L, Guthold R, Cowan M, Savin S, Bhatti L, Armstrong T, Bonita R. The World Health Organization STEPwise Approach to Noncommunicable Disease Risk-Factor Surveillance: Methods, Challenges, and Opportunities. Am J Public Health. 2016 Jan;106(1):74-8. doi: 10.2105/AJPH.2015.302962. 
  2. Kurbanov R.D., Khamidullaeva G.A. Arterial hypertension. Monograph. Tashkent: "Noshirlik Yog'dusi"; 2017. [In Uzbek].
  3. Khamidullaeva GA, Tursunova NB, Abdullaeva GZh, Masharipov ShM, et al. Identification of truly resistant hypertension and the effectiveness of multicomponent antihypertensive therapy. Trudnyi Pazient. 2019;17(11-12):6-11. {Article in Russian].
  4. Karpov IuA, Deev AD. [Uncontrolled arterial hypertension--new possibilities in solving problems of increasing the effectiveness of treatment]. Kardiologiia. 2012;52(2):29-35.[Article in Russian].
  5. Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, et al.; American Heart Association Professional/Public Education and Publications Committee of the Council on Hypertension; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Genomic and Precision Medicine; Council on Peripheral Vascular Disease; Council on Quality of Care and Outcomes Research; and Stroke Council. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. Hypertension. 2018 Nov;72(5):e53-e90. doi: 10.1161/HYP.0000000000000084.
  6. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al.; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018 Sep 1;39(33):3021-3104. doi: 10.1093/eurheartj/ehy339. Erratum in: Eur Heart J. 2019 Feb 1;40(5):475. 
  7. Voigt JU, Pedrizzetti G, Lysyansky P, Marwick TH, Houle H, Baumann R, et al. Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. Eur Heart J Cardiovasc Imaging. 2015;16(1):1-11. doi: 10.1093/ehjci/jeu184.
  8. Devereux RB, de Simone G, Ganau A, Roman MJ. Left ventricular hypertrophy and geometric remodeling in hypertension: stimuli, functional consequences and prognostic implications. J Hypertens Suppl. 1994;12(10):S117-27.
  9. Rimoldi SF, Messerli FH, Bangalore S, Scherrer U. Resistant hypertension: what the cardiologist needs to know. Eur Heart J. 2015 Oct 21;36(40):2686-95. doi: 10.1093/eurheartj/ehv392. 
  10. Petersen J, Malyutina S, Ryabikov A, Kontsevaya A, Kudryavtsev AV, Eggen AE, McKee M, Cook S, Hopstock LA, Schirmer H, Leon DA. Uncontrolled and apparent treatment resistant hypertension: a cross-sectional study of Russian and Norwegian 40-69 year olds. BMC Cardiovasc Disord. 2020 Mar 13;20(1):135. doi: 10.1186/s12872-020-01407-2. 
  11. Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K, Velazquez EJ, Staikos-Byrne L, Kelly RY, Shi V, Chiang YT, Weber MA; ACCOMPLISH Trial investigators. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet. 2010 Apr 3;375(9721):1173-81. doi: 10.1016/S0140-6736(09)62100-0. 
  12. National Clinical Guideline Centre (UK). Hypertension: The Clinical Management of Primary Hypertension in Adults: Update of Clinical Guidelines 18 and 34 [Internet]. London: Royal College of Physicians (UK); 2011 Aug.
  13. Falaschetti E, Mindell J, Knott C, Poulter N. Hypertension management in England: a serial cross-sectional study from 1994 to 2011. Lancet. 2014 May 31;383(9932):1912-9. doi: 10.1016/S0140-6736(14)60688-7. 
  14. Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich). 2014 Jan;16(1):14-26. doi: 10.1111/jch.12237. 
  15. Patel A; ADVANCE Collaborative Group, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, et al. B. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007 Sep 8;370(9590):829-40. doi: 10.1016/S0140-6736(07)61303-8.
  16. Tóth K; PIANIST Investigators. Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus AmlodipiNe in high rISk hyperTensive patients). Am J Cardiovasc Drugs. 2014 Apr;14(2):137-45. doi: 10.1007/s40256-014-0067-2. Erratum in: Am J Cardiovasc Drugs. 2014 Jun;14(3):239. 
  17. Nedogoda SV, Stojanov VJ. Single-Pill Combination of Perindopril/Indapamide/Amlodipine in Patients with Uncontrolled Hypertension: A Randomized Controlled Trial. Cardiol Ther. 2017 Jun;6(1):91-104. doi: 10.1007/s40119-017-0085-7. 
  18. Mazza A, Lenti S, Schiavon L, Sacco AP, Dell'Avvocata F, Rigatelli G, Ramazzina E. Fixed-Dose Triple Combination of Antihypertensive Drugs Improves Blood Pressure Control: From Clinical Trials to Clinical Practice. Adv Ther. 2017 Apr;34(4):975-985. doi: 10.1007/s12325-017-0511-1. 
  19. Stafylas P, Kourlaba G, Hatzikou M, Georgiopoulos D, Sarafidis P, Maniadakis N. Economic evaluation of a single-pill triple antihypertensive therapy with valsartan, amlodipine, and hydrochlorothiazide against its dual components. Cost Eff Resour Alloc. 2015 Jun 9;13:10. doi: 10.1186/s12962-015-0036-x. 
  20. Takagi H, Niwa M, Mizuno Y, Goto SN, Umemoto T; All-Literature Investigation of Cardiovascular Evidence Group. A meta-analysis of randomized trials of telmisartan versus losartan for reduction of ambulatory blood pressure. Hypertens Res. 2013 Nov;36(11):959-66. doi: 10.1038/hr.2013.78.

Download Article
Received September 15, 2020.
Accepted December 3, 2020.
©2020 International Medical Research and Development Corporation.